NPS Pharmaceuticals to Present at Two Upcoming Conferences (NPSP)

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 9th Annual Needham Healthcare Conference in New York on Wednesday, June 9, 2010 at 10:40 a.m. ET and the Jefferies 2010 Global Life Sciences Conference in New York on Friday, June 11, 2010 at 10:00 a.m. ET. Presentations will be available as live webcasts with replays available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS website at http://www.npsp.com.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX(R) in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and is in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at http://www.npsp.com.

SOURCE: NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335